BioTalk
'We are looking at 400% growth' - Dr B V Ravi Kumar, founder chairman and MD, XCyton Diagnostics
'We have a strong and diversified pipeline of novel targets' - Dr Suri Venkatchalam, CEO, Connexios Life Sciences
BioComment
CROs on budget blind spot
BioPolicy
India to control FMD in cattle
|
BioAnalysis
India allows compulsory licensing of Bayer
BioServices
'We provide services to 14 of the top 20 pharma companies' - Mr Swapan Bhattacharya, MD,TCG Life Sciences
BioSupplier
'Our plan is further growth in classical pharmaceuticals' - Mr M S Mahadevan, CEO, Biozeen
'Third generation sequencing is superior to NGS' - Mr Neeraj Gupta, director - sales & marketing, Imperial Life Sciences, Gurgaon
|